

The clinical evaluation and decision making associated with the management of unruptured intracranial aneurysms are complex. In the past 5 years, studies have evaluated the benefits of screening in people at high-risk, such as those with a family history of aneurysmal subarachnoid haemorrhage or unruptured intracranial aneurysms, people with genetic or other disorders associated with intracranial aneurysms, and people who smoke and have hypertension. If an aneurysm is detected during screening or incidentally, prediction models now allow for estimating the risk of complications from preventive aneurysm occlusion.
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet